SEARCH:   Advanced

Blood, 15 November 2004, Vol. 104, No. 10, pp. 3058-3063. Prepublished online as a Blood First Edition Paper on June 24, 2004; DOI 10.1182/blood-2003-12-4347. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4347v1 104/10/3058    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tse, W. Articles by Radich, J. P. Search for Related Content PubMed PubMed Citation Articles by Tse, W. Articles by Radich, J. P. Related Collections Oncogenes and Tumor Suppressors Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia William Tse, Soheil Meshinchi, Todd A. Alonzo, Derek L. Stirewalt, Robert B. Gerbing, William G. Woods, Frederick R. Appelbaum, and Jerald P. Radich From the Fred Hutchinson Cancer Research Center; the Department of Medicine and Department of Pediatrics, University of Washington School of Medicine, Seattle; Department of Medicine, University Hospital of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH; the Department of Pediatric Hematology/Oncology, Emory University School of Medicine, Atlanta, GA; the Department of Biostatistics, University of Southern California Keck School of Medicine, Los Angeles; and the Children's Oncology Group, Arcadia, CA. The AF1q gene, a mixed-lineage leukemia fusion partner, is highly expressed in hematopoietic progenitor cells but has low expression in differentiated cells. We determined the expression of the AF1q gene by reverse transcriptase–polymerase chain reaction in 64 pediatric acute myeloid leukemia (AML) patients treated on Children's Cancer Group clinical trial CCG-2891 and correlated its expression level to clinical characteristics and outcome. AF1q expression in patients varied from 0- to 154-fold compared with normal marrow, and increasing expression level was associated with worsening survival, with a hazard ratio of 1.02 per fold increase in AF1q expression (P = .032). We divided patients into tertile groups based on AF1q expression level. Patients with high AF1q expression (top tertile) had a higher predominance of French-American-British M1 compared to patients with lower 2 tertiles of AF1q expression (43% vs 9%, P = .003). High AF1q expression was associated with poor survival in univariate and multivariate models. Overall survival at 8 years for patients with the high AF1q expression was 19% versus 50% in patients with low AF1q expression, (P = .01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, S. Ricci, C. Orlandini, U. Boggi, D. Campani, M. Del Chiaro, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., April 1, 2006; 66(7): 3928 - 3935. [Abstract] [Full Text] [PDF] C. Jacques, O. Baris, D. Prunier-Mirebeau, F. Savagner, P. Rodien, V. Rohmer, B. Franc, S. Guyetant, Y. Malthiery, and P. Reynier Two-Step Differential Expression Analysis Reveals a New Set of Genes Involved in Thyroid Oncocytic Tumors J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2314 - 2320. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020